Why the study?
Efforts over decades to develop live attenuated virus vaccines against tick-borne encephalitis virus with acceptable safety and immunogenicity characteristics have not been successful.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
MicroRNA-targeted TBEV LAV shows strong attenuation and immunogenicity; leaves open human trials to confirm safety and protective efficacy.
Tick-borne encephalitis virus (TBEV) is one of the most medically important tick-borne pathogens of the Old World. Despite decades of active research, efforts to develop of TBEV live attenuated virus (LAV) vaccines with acceptable safety and immunogenicity characteristics have not been successful. Here we report the development and evaluation of a highly attenuated and immunogenic microRNA-targeted TBEV LAV.
No takes yet. Share an insight, caveat, or question.
Tsetsarkin et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: